





RealRate

PHARMACEUTICAL 2017

DYNAVAX TECHNOLOGIES CORP Rank 159 of 292

DYNAVAX

The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 34% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Net Income, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 62%, being 60% points above the market average of 2.9%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 89,599 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 1,971 |
| Liabilities, Current | 20,036 |
| Liabilities, Non-Current | 443 |
| Other Assets | 936 |
| Other Compr. Net Income | -694 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | -1,737 |
| Other Revenues | 11,043 |
| Property and Equipment | 17,174 |
| Research and Development | 84,493 |
| Selling, General and Administrative Expense | 37,257 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 109,680 |
| Liabilities | 20,479 |
| Expenses | 121,750 |
| Revenues | 11,043 |
| Stockholders Equity | 89,201 |
| Net Income | -112,444 |
| Comprehensive Net Income | -112,791 |
| Economic Capital Ratio | 62% |